Description
TB-500 — Research Peptide (10 mg)
TB-500 is a synthetic analog of thymosin beta-4 (T?4), examined in
preclinical models for roles in cytoskeletal dynamics, cell migration, angiogenesis, and wound remodeling.
While it is frequently studied on its own, TB-500 is also a common research partner to
BPC-157, with TB-500 emphasizing actin-related motility and re-epithelialization biology.
What It Is
- TB-500: 43-amino-acid analog of thymosin ?4, investigated for actin binding/sequestration,
cell motility, microtubule/cytoskeleton remodeling, and re-epithelialization in injury models.
Proposed Mechanisms (Preclinical)
- Actin-binding motif
LKKTETQassociated with cytoskeletal reorganization and cell motility. - Wound-healing biology: re-epithelialization, angiogenesis, and granulation-tissue quality (model-dependent).
- Inflammation-pathway modulation (e.g., miR-146a/IRAK1/TRAF6 axis, exploratory).
Selected Research Highlights
- Skin/Wound Models: TB-500 (T?4) has been associated with faster re-epithelialization and
contraction vs. controls in animal studies; small clinical datasets in chronic wounds have explored
dose-response over multi-week protocols. - Tendon/Ligament: TB-family peptides have been reported to support more organized collagen
and improved mechanical properties post-injury. - Muscle & Cardiac Models: Investigated for cytoskeletal remodeling and angiogenesis in
skeletal-muscle injury and cardiac ischemia models.
Combining TB-500 with BPC-157 in Research
In many experimental frameworks, TB-500 is paired with BPC-157 to evaluate
complementary pathways: TB-500 for actin-based cell motility and re-epithelialization; BPC-157 for endothelial
integrity, angiogenic signaling, and matrix organization. Researchers may compare TB-500 alone vs.
TB-500 + BPC-157 to study potential additive effects on capillary density, ECM quality, and repair-related
signaling.
For teams that prefer a unified preparation, MyPurePeptide also provides a
BPC-157 & TB-500 Research Peptide Blend, allowing investigation of the combination
in a single co-formulated vial.
Chemical Information
- TB-500 — Formula: C212H350N56O78S ·
MW: 4963 g/mol - Content per vial: 10 mg TB-500 (lyophilized powder)
Specifications
- Form: Lyophilized powder (research-grade)
- Purity: ?99% (HPLC); COA per lot available
- Packaging: Sealed vials suitable for laboratory handling
Storage & Handling
- Store lyophilized vials in a cool, dry place, protected from light.
- After reconstitution: refrigerate at 2–8 °C.
- For long-term stability: store at ?20 °C; avoid repeated freeze–thaw cycles.
.mpp-prose .mpp-cols{
display:grid;
gap:14px;
}
@media (min-width:700px){
.mpp-prose .mpp-cols{
grid-template-columns:1fr 1fr;
}
}
.mpp-prose h2,
.mpp-prose h3{
margin:.2em 0 .35em;
}
.mpp-prose h4{
margin:.2em 0 .25em;
}
.mpp-prose ul{
margin:.2em 0 .6em;
padding-left:1.1em;
}
.mpp-prose p{
margin:.4em 0 .8em;
line-height:1.55;
}
.mpp-prose code{
background:#f6f8fb;
border:1px solid #e5e7eb;
border-radius:6px;
padding:.04em .35em;
}


Reviews
There are no reviews yet.